Skip to Main Content

This website uses cookies to ensure you have the best user experience. By continuing to use this website, you consent to our use of cookies. For more information, read our privacy policy.

This is a test.

NEOCATS trial: Targeting the targets with a combination of three treatments

This is a test.

ES2 trial: combining a PARP inhibitor and apoptosis sensitizer

This is a test.

Phase II clinical trial of CX5461 at the time of disease progression on a PARP inhibitor

This is a test.

Re-VOLVE trial: using genomics to make treatment decisions after a PARP inhibitor

This is a test.

Tumour testing and ovarian cancer drug prediction program